Incyte Corporation
115.71USD
-1.2200 (-1.04%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on INCY.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$3.85▼ | -$3.49 | 0 | 2 |
| Next quarter | $1.94▼ | $2.15 | 1 | 2 |
| Current year | $3.1▲ | $2.64 | 0 | 3 |
| Next year | $8.64▼ | $9.03 | 0 | 5 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.15 | $3.09 | +0.94 (+43.9%) |
| 2026-03-31 | $1.34 | $1.81 | +0.47 (+35.1%) |
| 2025-12-31 | $1.92 | $1.8 | -0.12 (-6.1%) |
| 2025-09-30 | $1.64 | $2.26 | +0.62 (+38.0%) |
358 ratings from 41 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Buy | $138 $140 | Oct 21, 2026 |
| Truist Securities | Maintained | Hold | $105 $115 | Oct 14, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $152 | Oct 13, 2026 |
| RBC Capital | Maintained | Sector Perform | $109 $114 | Oct 8, 2026 |
| Stifel | Maintained | Buy | $145 $157 | Oct 5, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $116 $128 | Oct 1, 2026 |
| JP Morgan | Maintained | Neutral | $120 $123 | Sep 28, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $150 $152 | Sep 28, 2026 |
| RBC Capital | Reiterated | Sector Perform | $109 | Sep 22, 2026 |
| Canaccord Genuity | Initiated | Buy | $152 | Aug 20, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $150 | Aug 20, 2026 |
| Piper Sandler | Maintained | Overweight | $110 $130 | Aug 17, 2026 |
| Mizuho | Maintained | Outperform | $121 $137 | Aug 4, 2026 |
| Leerink Partners | Maintained | Outperform | $131 $155 | Aug 3, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $150 | Aug 3, 2026 |
| RBC Capital | Maintained | Sector Perform | $99 $109 | Jul 29, 2026 |
| Guggenheim | Maintained | Buy | $136 $150 | Jul 29, 2026 |
| BMO Capital | Maintained | Market Perform | $112 $130 | Jul 29, 2026 |
| Barclays | Maintained | Overweight | $134 $139 | Jul 29, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $140 $150 | Jul 29, 2026 |
| JP Morgan | Maintained | Neutral | $105 $110 | Jul 23, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $103 $104 | Jul 23, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $140 | Jul 21, 2026 |
| Barclays | Maintained | Overweight | $117 $134 | Jul 14, 2026 |
| BMO Capital | Maintained | Market Perform | $94 $112 | Jul 13, 2026 |
176 filings from 33 insiders · 30 buy / 14 sell over 6m
Officers and directors of INCY, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| CAGNONI PABLO JOfficer, President, Global Head of R&D | ExerciseEmployee Stock Option (right to buy) | 925 | — | — | Oct 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | ExerciseEmployee Stock Option (right to buy) | 455 | — | — | Oct 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | ExerciseEmployee Stock Option (right to buy) | 423 | — | — | Oct 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | ExerciseEmployee Stock Option (right to buy) | 839 | — | — | Oct 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | Sell | 2.6k | $112.71 | $298k | Oct 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | Exercise | 925 | $64.25 | $59k | Oct 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | Exercise | 455 | $61.18 | $28k | Oct 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | Exercise | 423 | $61.76 | $26k | Oct 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | Exercise | 839 | $71.93 | $60k | Oct 15, 2026 |
| Heeson LeeOfficer, EVP, Head of Incyte Intl | Tax | 463 | $117.14 | $54k | Oct 1, 2026 |
| Clancy Paul JDirector | Grant | 203 | $121.35 | $25k | Sep 30, 2026 |
| BAKER BROS. ADVISORS LPDirector; 10% owner | Grantindirect | 322 | — | — | Sep 30, 2026 |
| BAKER BROS. ADVISORS LPDirector; 10% owner | Grantindirect | 322 | — | — | Sep 30, 2026 |
| HARRIGAN EDMUNDDirector | Grant | 206 | $121.35 | $25k | Sep 30, 2026 |
| Gardner David HOfficer, EVP, Chief Strategy Officer | Tax | 920 | $126.93 | $117k | Sep 22, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | ExerciseEmployee Stock Option (right to buy) | 9.2k | — | — | Sep 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | ExerciseEmployee Stock Option (right to buy) | 6.5k | — | — | Sep 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | ExerciseEmployee Stock Option (right to buy) | 4.6k | — | — | Sep 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | ExerciseEmployee Stock Option (right to buy) | 3.0k | — | — | Sep 15, 2026 |
| CAGNONI PABLO JOfficer, President, Global Head of R&D | Sell | 14.0k | $120.49 | $1.69M | Sep 15, 2026 |
No analyst notes on INCY yet.
Analyst Ratings
24 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 10 | 15 | 0 | 1 | Hold2.57 |
| 1 mo ago | 2 | 10 | 15 | 1 | 0 | Hold2.54 |
| 2 mo ago | 2 | 10 | 15 | 1 | 0 | Hold2.54 |
| 3 mo ago | 2 | 9 | 15 | 1 | 0 | Hold2.56 |
Members whose judged calls on INCY have played out most reliably.
No settled calls on INCY yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice